Group One Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-14,925
Closed -$350K 8066
2025
Q3
$338K Sell
14,925
-1,853
-11% -$43.2K ﹤0.01% 4111
2025
Q2
$290K Sell
16,778
-13,263
-44% -$246K ﹤0.01% 3961
2025
Q1
$657K Buy
+30,041
New +$830K ﹤0.01% 2827
2024
Q4
Sell
-42,153
Closed -$1.27M 7223
2024
Q3
$1.22M Buy
42,153
+7,454
+21% +$276K ﹤0.01% 2135
2024
Q2
$1.33M Buy
+34,699
New +$1.57M 0.01% 1764
2024
Q1
Sell
-253,905
Closed -$16.2M 6994
2023
Q4
$15.2M Buy
253,905
+27,221
+12% +$1.38M 0.04% 462
2023
Q3
$8.62M Buy
226,684
+207,866
+1,105% +$9.13M 0.03% 600
2023
Q2
$1.71M Buy
18,818
+13,908
+283% +$1.2M 0.01% 1857
2023
Q1
$324K Sell
4,910
-45,913
-90% -$2.65M ﹤0.01% 3186
2022
Q4
$2.63M Buy
+50,823
New +$2.7M 0.01% 1604
2022
Q3
Sell
-25,823
Closed -$1.53M 7505
2022
Q2
$1.17M Sell
25,823
-29,723
-54% -$1.36M ﹤0.01% 2599
2022
Q1
$2.82M Buy
55,546
+19,525
+54% +$862K ﹤0.01% 2055
2021
Q4
$1.7M Sell
36,021
-69,731
-66% -$2.75M ﹤0.01% 2784
2021
Q3
$3.49M Buy
+105,752
New +$5.94M ﹤0.01% 2071
2020
Q4
Sell
-1,629
Closed -$68.9K 6445
2020
Q3
$49K Buy
+1,629
New +$48.7K ﹤0.01% 4653
2019
Q4
Sell
-100
Closed -$2.77K 5085
2019
Q3
$2K Buy
+100
New +$2.75K ﹤0.01% 4901

Other funds holding APLS

Group One Trading's APLS Position: Q4 2025 in Review

Group One Trading sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 14,925 shares — an estimated $350K sold.

Group One Trading first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $15.2M in Q4 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Group One Trading reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 14,925 Apellis Pharmaceuticals shares in Q4 2025, an estimated $350K.
  • Group One Trading first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
  • Group One Trading's Apellis Pharmaceuticals position peaked at $15.2M in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.